BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zanker DJ, Spurling AJ, Brockwell NK, Owen KL, Zakhour JM, Robinson T, Duivenvoorden HM, Hertzog PJ, Mullins SR, Wilkinson RW, Parker BS. Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. Clin Transl Immunology 2020;9:e1177. [PMID: 33005415 DOI: 10.1002/cti2.1177] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Baldwin LA, Bartonicek N, Yang J, Wu SZ, Deng N, Roden DL, Chan C, Al-eryani G, Zanker DJ, Parker BS, Swarbrick A, Junankar S. DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. Nat Commun 2022;13:6539. [DOI: 10.1038/s41467-022-34041-x] [Reference Citation Analysis]
2 Aghamajidi A, Farhangnia P, Pashangzadeh S, Damavandi AR, Jafari R. Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy. Cancer Cell Int 2022;22:327. [PMID: 36303138 DOI: 10.1186/s12935-022-02727-3] [Reference Citation Analysis]
3 Li C, Pan J, Jiang Y, Wu Y, Jin Z, Chen X. Characterization of Pyroptosis-Related Subtypes via RNA-Seq and ScRNA-Seq to Predict Chemo-Immunotherapy Response in Triple-Negative Breast Cancer. Front Genet 2022;13:788670. [PMID: 35386285 DOI: 10.3389/fgene.2022.788670] [Reference Citation Analysis]
4 Liu Y, Li C, Xia H, Bi J, Guan R, Du X, Zhang H, He Z, Wang Y, Liu H. An injectable superior depot of Telratolimod inhibits post-surgical tumor recurrence and distant metastases. Acta Biomater 2022;141:132-9. [PMID: 35032721 DOI: 10.1016/j.actbio.2022.01.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zou X, Liu Y, Di J, Wei W, Watanabe N, Li J, Li X. ZMIZ2 promotes the development of triple-receptor negative breast cancer. Cancer Cell Int 2022;22:52. [PMID: 35101047 DOI: 10.1186/s12935-021-02393-x] [Reference Citation Analysis]
6 Yang S, Jackson C, Karapetyan E, Dutta P, Kermah D, Wu Y, Wu Y, Schloss J, Vadgama JV. Roles of Protein Disulfide Isomerase in Breast Cancer. Cancers (Basel) 2022;14:745. [PMID: 35159012 DOI: 10.3390/cancers14030745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Corti C, Nicolò E, Curigliano G. Novel immune targets for the treatment of triple-negative breast cancer. Expert Opin Ther Targets 2021;:1-20. [PMID: 34763593 DOI: 10.1080/14728222.2021.2006187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Al-Rashidi HE, Refaat S, Ahmed E, Hussein DT, Eltantawy FM, Hamed S. Involvement of INF-γ functional single nucleotide polymorphism +874 T/A (rs2430561) in breast cancer risk. Saudi J Biol Sci 2021;28:6289-96. [PMID: 34759748 DOI: 10.1016/j.sjbs.2021.06.083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Tarantino P, Antonarelli G, Ascione L, Curigliano G. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opin Investig Drugs 2021;:1-15. [PMID: 34569405 DOI: 10.1080/13543784.2021.1972968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Mattiuz R, Brousse C, Ambrosini M, Cancel JC, Bessou G, Mussard J, Sanlaville A, Caux C, Bendriss-Vermare N, Valladeau-Guilemond J, Dalod M, Crozat K. Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T-cell protective responses to breast cancer. Clin Transl Immunology 2021;10:e1305. [PMID: 34277006 DOI: 10.1002/cti2.1305] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
11 Itai Y, Ueda Y, Etoh T, Shirasaka Y, Shiroshita H, Shiraishi N, Daa T, Inomata M. Clinical significance of sarcoid-like reaction in lymph nodes of gastric cancer patients. J Surg Oncol 2021;124:293-300. [PMID: 34003494 DOI: 10.1002/jso.26525] [Reference Citation Analysis]
12 Fenton SE, Saleiro D, Platanias LC. Type I and II Interferons in the Anti-Tumor Immune Response. Cancers (Basel) 2021;13:1037. [PMID: 33801234 DOI: 10.3390/cancers13051037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 18.0] [Reference Citation Analysis]
13 Burn OK, Prasit KK, Hermans IF. Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists. Cancers (Basel) 2020;12:E3824. [PMID: 33352882 DOI: 10.3390/cancers12123824] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
14 Wang M, Wang S, Desai J, Trapani JA, Neeson PJ. Therapeutic strategies to remodel immunologically cold tumors. Clin Transl Immunology 2020;9:e1226. [PMID: 35136604 DOI: 10.1002/cti2.1226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]